Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric S Daar

Showing results (101-110 of 222) with videos related to

Pageof 23
Sort By:
HIV Clinical Trials|January 31, 2017
HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimenMaile Y Karris, Sonia Jain, Tyler R C Day, et al.
Annals of Internal Medicine|July 1, 2014
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial dataKatie R Mollan, Marlene Smurzynski, Joseph J Eron, et al.
Journal of Virology|December 23, 2004
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strainsOtto O Yang, Eric S Daar, Beth D Jamieson, et al.
Ebiomedicine|November 13, 2022
Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trialHonghu Liu, Yan Wang, Yilan Huang, et al.
The Journal of Infectious Diseases|August 31, 2023
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment TrialKara W Chew, Carlee Moser, Eunice Yeh, et al.
Open Forum Infectious Diseases|April 18, 2015
Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group ProtocolsCarrie B Moore, Anurag Verma, Sarah Pendergrass, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|December 31, 2023
Lymphocyte Count Derived Polygenic Score and Interindividual Variability in CD4 T-cell Recovery in Response to Antiretroviral TherapyKathleen M Cardone, Scott Dudek, Karl Keat, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 5, 2010
Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200Michael F Para, Jeff Schouten, Susan L Rosenkranz, et al.
The Journal of Infectious Diseases|August 31, 2023
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 TrialCarlee B Moser, Kara W Chew, Justin Ritz, et al.
AIDS and Behavior|May 1, 2020
Greater Levels of Self-Reported Adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with Increased Condomless Sex Among Men Who Have Sex with MenElizabeth C Pasipanodya, Michael J Li, Sonia Jain, et al.
Pageof 23

Showing results (101-110 of 222) with videos related to

Sort By:
Pageof 23
HIV Clinical Trials|January 31, 2017
HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimenMaile Y Karris, Sonia Jain, Tyler R C Day, et al.
Annals of Internal Medicine|July 1, 2014
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial dataKatie R Mollan, Marlene Smurzynski, Joseph J Eron, et al.
Journal of Virology|December 23, 2004
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strainsOtto O Yang, Eric S Daar, Beth D Jamieson, et al.
Ebiomedicine|November 13, 2022
Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trialHonghu Liu, Yan Wang, Yilan Huang, et al.
The Journal of Infectious Diseases|August 31, 2023
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment TrialKara W Chew, Carlee Moser, Eunice Yeh, et al.
Open Forum Infectious Diseases|April 18, 2015
Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group ProtocolsCarrie B Moore, Anurag Verma, Sarah Pendergrass, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|December 31, 2023
Lymphocyte Count Derived Polygenic Score and Interindividual Variability in CD4 T-cell Recovery in Response to Antiretroviral TherapyKathleen M Cardone, Scott Dudek, Karl Keat, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 5, 2010
Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200Michael F Para, Jeff Schouten, Susan L Rosenkranz, et al.
The Journal of Infectious Diseases|August 31, 2023
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 TrialCarlee B Moser, Kara W Chew, Justin Ritz, et al.
AIDS and Behavior|May 1, 2020
Greater Levels of Self-Reported Adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with Increased Condomless Sex Among Men Who Have Sex with MenElizabeth C Pasipanodya, Michael J Li, Sonia Jain, et al.
Pageof 23